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Abstract Therapeutic over-expression of vascular endo-
thelial growth factor (VEGF) can be used to treat ischemic
conditions. However, VEGF can induce either normal or
aberrant angiogenesis depending on its dose in the micro-
environment around each producing cell in vivo, which
limits its clinical usefulness. The goal herein was to deter-
mine the cellular mechanisms by which physiologic and
aberrant vessels are induced by over-expression of different
VEGF doses in adult skeletal muscle. We took advantage of a
well-characterized cell-based platform for controlled gene
expression in skeletal muscle. Clonal populations of retro-
virally transduced myoblasts were implanted in limb muscles
of immunodeficient mice to homogeneously over-express
two specific VEGF164 levels, previously shown to induce
physiologic and therapeutic or aberrant angiogenesis,
respectively. Three independent and complementary meth-
ods (confocal microscopy, vascular casting and 3D-recon-
struction of serial semi-thin sections) showed that, at both
VEGF doses, angiogenesis took place without sprouting, but
rather by intussusception, or vascular splitting. VEGF-
induced endothelial proliferation without tip-cell formation
caused an initial homogeneous enlargement of pre-existing
microvessels, followed by the formation of intravascular
transluminal pillars, hallmarks of intussusception. This was
associated with increased flow and shear stress, which are
potent triggers of intussusception. A similar process of
enlargement without sprouting, followed by intussusception,
was also induced by VEGF over-expression through a clin-
ically relevant adenoviral gene therapy vector, without the
use of transduced cells. Our findings indicate that VEGF
over-expression, at doses that have been shown to induce
functional benefit, induces vascular growth in skeletal mus-
cle by intussusception rather than sprouting.
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Abbreviations
VEGF Vascular endothelial growth factor
NG2 Nerve/glial antigen-2
SMA Smooth muscle actin
KLF-2 Kru¨ppel-like factor-2
eNOS Endothelial nitric oxide synthase
IRES Internal rybosomal entry site
FACS Fluorescence activated cell sorter
SCID Severe combined immunodeficiency
Introduction
Angiogenesis, i.e. the growth of new blood vessels from
pre-existing ones, is a process that can be targeted to
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restore blood supply to ischemic tissues. Vascular endo-
thelial growth factor (VEGF) is the master regulator of
vascular growth both in development and disease and, upon
expression as a single factor, is capable of initiating the
cascade of events leading from endothelial activation to the
generation of new functional and stable vascular networks
[1]. However, we previously found that VEGF can induce
the growth of either normal capillary networks or aberrant
angioma-like structures depending on its expression level
in the microenvironment around each producing cell in
vivo and not on the total dose delivered, since it remains
tightly bound to the extracellular matrix [2, 3]. The need to
strictly control VEGF dose distribution in vivo poses a
major challenge to its therapeutic exploitation [4–6].
Understanding how normal or aberrant vessels are formed
after expression of specific VEGF doses is crucial to design
new rational therapeutic strategies. Our current compre-
hension of the initiation of vessel growth is mostly based
on powerful genetic models of developmental angiogene-
sis, in which new vessels sprout to invade and vascularize
non-perfused tissue, such as the newborn mouse retina [7].
However, in skeletal and cardiac muscle, which are the
target tissues of ischemia treatments, extensive pre-existing
vascular networks are present, from which new vessels are
induced therapeutically by over-expression of factors well
above endogenous levels.
Skeletal muscle angiogenesis has been shown to take
place by sprouting after up-regulation of endogenous
VEGF expression, for example during the adaptation to
exercise training [8, 9] or in the reparative response to
ischemia [10]. However, several studies found that vascular
growth in skeletal muscle can also take place through
another complementary mechanism called intussusception,
or splitting angiogenesis. Characteristic for this process is
the formation of transluminal pillars, which fuse progres-
sively together and split the affected vascular segment [11].
Key stimuli to initiate pillar formation have been found to
be increased blood flow and shear stress [12–14]. Initial
pillar formation can occur either through a zone of contact
between the endothelial cells of opposite capillary walls,
with subsequent reorganization of the endothelial junctions
and invasion of the pillar core by myofibroblasts [15, 16],
or through the extension and fusion of intraluminal pro-
trusions made exclusively of endothelial cells [17]. It is not
yet clear whether these two processes take place in dif-
ferent kinds of vessels, but eventually both lead to the
generation of new vascular segments by longitudinal
splitting rather than by ab-luminal sprouting.
Therefore, we took advantage of a unique and well-
characterized cell-based platform for controlled gene
expression in skeletal muscle [2, 3, 18] to investigate the
cellular mechanisms by which specific VEGF doses across
the therapeutic to toxic range induce normal or aberrant
angiogenesis in clinically relevant conditions.
Methods
Cell culture
Primary myoblasts isolated from C57BL/6 mice and
already transduced with a retrovirus expressing the b-gal
marker gene were further infected at high efficiency, as
previously described [19], with a retroviral construct car-
rying the cDNA for murine VEGF164 linked through an
Internal Ribosomal Entry Sequence (IRES) to a truncated
version of murine CD8a (trCD8a) [18]. Control CD8 cells
expressed only trCD8a and no VEGF. Early-passage
myoblast clones were isolated using a FACS Vantage SE
cell sorter (Becton–Dickinson, Basel, Switzerland) and
single cell isolation was confirmed visually. All myoblast
populations were cultured in 5 % CO2 on collagen-coated
dishes, with a growth medium consisting of 40 % F10,
40 % DMEM (Sigma-Aldrich Chemie GmbH, Steinheim,
Germany) and 20 % fetal bovine serum (HyClone, Logan,
UT), supplemented with 2.5 ng/ml FGF-2 (R&D Systems,
Abingdon, UK), as described [20].
VEGF164 ELISA measurements
The production of VEGF164 in cell culture supernatants
was quantified using a Quantikine mouse VEGF Immu-
noassay ELISA kit (R&D Systems, Abingdon, UK). One
ml of medium was harvested from myoblasts in one 60 mm
dish, following a 4-h incubation, filtered and analyzed in
duplicate. Results were normalized for the number of cells
in the dish and time of exposure to medium. Four dishes of
cells were assayed per cell type (n = 4).
Myoblast implantation into mice
Cells were implanted into 5–10 week-old immunodeficient
SCID CB.17 mice (Charles River Laboratories, Sulzfeld,
Germany) in order to avoid an immunological response to
b-galactosidase-expressing myoblasts. Animals were trea-
ted in accordance with Swiss Federal guidelines for animal
welfare and the study protocol was approved by the
Veterinary Office of the Canton Basel-Stadt (Basel,
Switzerland). Myoblasts were dissociated in trypsin and
resuspended at a concentration of 108 cells/ml in sterile
PBS with 0.5 % BSA. 1 9 106 cells in 10 ll were
implanted into the posterior auricular muscle, midway up
the dorsal aspect of the external ear, or into the tibialis
anterior (TA) and gastrocnemius (GC) muscles of the leg,
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using a syringe with a 291/2G needle, as previously
described [2].
Recombinant adenovirus production
Recombinant adenoviruses expressing either mouse
VEGF164 linked to truncated CD8a in a bicistronic cassette,
or only CD8a as control, were produced using the Adeno-
XTM Expression System (Clontech, Saint-Germain-en-
Laye, France) according to manufacturer’s recommenda-
tions. Briefly, target genes were cloned into the pShuttle
vector, sub-cloned into the Adeno-X viral DNA and used to
transfect HEK 293 cells with Fugene HD reagent (Roche
Applied Science, Basel, Switzerland). After 1 week, viral
particles were collected from transfected cells by repeated
freezing–thawing and used for re-infection of fresh HEK
293. After 4–5 lysis and infection cycles, viral particles
were collected and purified by a double cesium chloride
gradient. Viral titer was determined as infectious units after
serial infection of HEK 293 cells at different multiplicities
of infection, as previously described [21]. Adenoviral
vectors were diluted in physiological solution and 20 ll
were injected in Tibialis Anterior muscles of SCID mice at
the titer of 5 9 109 infectious units/ml.
Tissue staining
The entire vascular network of the ear could be visualized
after intravascular staining with a biotinylated Lycopers-
icon esculentum (tomato) lectin (Vector Laboratories,
Burlingame, CA, USA) that binds the luminal surface of all
blood vessels, as previously described [2]. Briefly, mice
were anesthetized, lectin was injected intravenously
(100 ll per mouse of lectin resuspended at 1 mg/ml) and
4 min later the tissues were fixed by vascular perfusion of
1 % paraformaldehyde and 0.5 % glutaraldehyde in PBS
pH 7.4 under 120 mm/Hg of pressure. Ears were then
removed, bisected in the plane of the cartilage, and stained
with X-gal staining buffer (1 mg/ml 5-bromo-4-chloro-3-
indoyl-b-D-galactoside, 5 mM potassium ferricyanide,
5 mM potassium ferrocyanide, 0.02 % Nonidet P-40,
0.01 % sodium deoxycholate, 1 mM MgCl2 in PBS pH
7.4). Tissues were stained using avidin–biotin complex-
diaminobenzidine histochemistry (Vector Laboratories,
Burlingame, CA, USA), dehydrated through an alcohol
series, cleared with toluene and whole-mounted on glass
slides with Permount embedding medium (Fisher Scien-
tific, Wholen, Switzerland). Vascular morphology was
analyzed at 4 days and 7 days after implantation for spe-
cific experiments.
For tissue sections, mice were anesthetized and the tissues
were fixed by vascular perfusion of 1 % paraformaldehyde in
PBS pH 7.4 for 4 min under 120 mm/Hg of pressure. TA and
GC muscles were harvested, embedded in OCT compound
(CellPath, Newtown, Powys, UK), frozen in freezing iso-
pentane and cryosectioned. Tissue sections were then stained
with X-gal (20 lm sections) to reveal myoblast engraftment
or with H&E (10 lm sections) as described previously [22,
23]. Immunofluorescence staining was performed on 12 lm-
thick frozen sections of muscles tissues, cut along the longi-
tudinal axis and on ear whole mounts. The following primary
antibodies and dilutions were used: rat anti-CD31 (clone
MEC 13.3, BD Biosciences, Basel, Switzerland) at 1:100; rat
anti-endomucin (clone V.7C7, Santa Cruz Biotechnology,
Santa Cruz, CA, USA) at 1:100; mouse anti-a-SMA (clone
1A4, MP Biomedicals, Basel, Switzerland) at 1:400; rabbit
anti-NG2 (Chemicon International, Hampshire, UK) at 1:200;
chicken anti-laminin (Abcam, Cambridge, UK) at 1:100;
rabbit anti-Ki67 (Abcam, Cambridge, UK) at 1:100. Fluo-
rescently labeled secondary antibodies (Invitrogen, Basel,
Switzerland) were used at 1:200. Fluorescence images were
taken with 409 or 639 objectives on a Carl Zeiss LSM710
3-laser scanning confocal microscope (Carl Zeiss, Feldbach,
Switzerland). All image analyses were performed with LSM
software Zen 2010 (Carl Zeiss, Feldbach, Switzerland).
Vessel analyses
Vessel diameters were measured in whole mounts of ears
stained with intravascular L. esculentum lectin perfusion as
described [2]. Briefly, vessel diameters were measured by
overlaying captured microscopic images with a square grid.
Squares were randomly chosen, and the diameter of each
vessel (if any) in the center of selected squares was mea-
sured. To avoid selection bias, we systematically measured
the shortest diameter in the selected vascular segment.
About 200 total vessel diameter measurements were
obtained from 3 to 5 fields (field size = 5750313 lm2)
from each of 6 analyzed ears per group (n = 6). All images
were taken with a 109 objective on an Olympus BX61
microscope (Olympus, Volketswil, Switzerland) and anal-
yses were performed with AnalySIS D software (Soft
Imaging System Gmbh, Mu¨nster, Germany).
Qualitative analysis of vascular morphology in immu-
nofluorescence images was performed on all vascular
structures visible in at least 3 fields/section (field
size = 450114 lm2) with a 409 objective in at least
5 sections/muscle, cut at 150 lm of distance from each
other, in 3 muscles/group. Therefore, at least 45 micro-
scopic fields were analyzed per group and time-point.
Ki67? endothelial cells were quantified from the total
amount of endothelial cells (300–800 total endothelial cells
were counted per condition and per time-point) in up to 3
vascular enlargements visible in each of 3–5 fields in each
area of effect (field size = 450114 lm2). At least five areas
with a clear angiogenic effect were analyzed per group.
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Vascular casting
Vascular casts were prepared similarly to the previously
described technique [24]. Briefly, the vasculature was
perfused with a freshly prepared solution of PU4ii polymer
(vasQtec, Zurich, Switzerland). One hour after perfusion,
the samples were transferred to 7.5 % potassium hydroxide
for dissolution of tissue, which was completed over
2–3 weeks. After washing, the casts were freeze-dried and
glued onto the aluminum sample stabs. The samples were
then sputtered with gold to a thickness of 10 nm and
examined in a Philips XL-30 SFEG scanning electron
microscope. Vascular enlargements were analyzed at least
in 5 fields per area of angiogenic effect in 3–4 leg muscles
(TA and GC) per group per time-point. TA received 1 cell
injection whereas GC received 2 cell implantations (in both
the medialis and lateralis portions). Quantification of the
numerical pillar density per microvessel area was per-
formed as previously described [25, 26]. Briefly, the total
number of pillars was counted per mm2 of vessel area (at
least 5 randomly chosen fields of vision (field size =
170549 lm2) within an area of effect were evaluated; C5
areas of effect in each muscle, n = 2 muscles). Holes
which were representative of pillars with diameter less than
1 lm or more than 10 lm were not considered.
Semi-thin serial sectioning
For the preparation of semi-thin sections of the implanted
muscles, mice were sacrificed by trans-cardiac intravas-
cular perfusion with a fixative solution composed of 2.5 %
(v/v) glutaraldehyde buffered in 0.03 M potassium phos-
phate (pH 7.4, 370 mOsm), under physiological pressure of
120 mm/Hg. The samples were then harvested and left
overnight in the same solution. They were then post-fixed
in 1 % OsO4 buffered with 0.1 M sodium cacodylate (pH
7.4, 340 mOsm), dehydrated in ethanol, and embedded in
epoxy resin (Sigma-Aldrich Co., St. Louis, MO, USA).
One-lm-thick serial sections were prepared using glass
knives and stained with Toluidine Blue (Sigma-Aldrich
Co., St. Louis, MO, USA). The serial sections were viewed
with a Leica DMRB light microscope (Leica microsystems,
Heerbrugg, Switzerland) and the images of implantation
sites were captured with a 409 objective using a SIS
ColorView 3U Camera (Olympus Europe Holding GmbH,
Hamburg, Germany). The set of images obtained was
aligned using Photoshop CS3 software (Adobe Systems,
San Jose, CA, USA) and imported as a stack into Imaris
Software (Bitplane, Zu¨rich, Switzerland) for 3D-recon-
struction and image analysis. Vascular enlargements were
analyzed in 3–5 fields (field size = 900220 lm2) per area
of effect. At least 5 areas were evaluated per muscle (n = 3
muscles per group per time-point, both TA and GC). TA
received 1 cell injection whereas GC received 2 cell
implantations (in both the medialis and lateralis portions).
Total RNA and genomic DNA co-isolation
and quantitative real-time PCR
Whole fresh mouse muscles were disrupted using a Qiagen
Tissue Lyser (Qiagen, Hombrechtikon, Switzerland) to
extract total RNA and genomic DNA with a DNA/RNA Mini
kit (Qiagen, Hombrechtikon, Switzerland), according to the
manufacturer’s instructions (n = 4 muscles (both TA and
GC) per group and per time-point). Total RNA was reverse-
transcribed into cDNA with the Omniscript Reverse Tran-
scription kit (Qiagen, Hombrechtikon, Switzerland) at 37 C
for 60 min. Quantitative Real-Time PCR (qRT-PCR) was
performed on an ABI 7300 Real-Time PCR system (Applied
Biosystems, Zug, Switzerland). To determine the expression
of the genes of interest the following TaqMan gene expres-
sion assays (Applied Biosystems, Zug, Switzerland) were
used: Nos3 (Mm00435217_m1), Klf2 (Mm01244979_g1)
and Gapdh housekeeping gene (Mm03302249_g1). The
cycling parameters were: 50 C for 2 min, followed by
95 C for 10 min and 40 cycles of denaturation at 95 C for
15 s and annealing/extension at 60 C for 1 min. Reactions
were performed in triplicate for each template, averaged, and
normalized to expression of the Gapdh housekeeping gene.
Statistical analysis
Data are presented as mean ± standard error. The signifi-
cance of differences was evaluated using analysis of variance
(ANOVA) followed by the Bonferroni test (for multiple
comparisons), or using a Student’s t test (for single com-
parisons). P \ 0.05 was considered statistically significant.
Results
VEGF over-expression induces both normal
and aberrant angiogenesis through initial vascular
enlargement
We investigated the initial vascular response to different
doses of murine VEGF164 in non-ischemic muscle of SCID
mice, to avoid the confounding effects of endogenous
factor up-regulation and inflammation that occur in ische-
mic tissue. To address this point, we took advantage of a
well-characterized pool of monoclonal populations of ret-
rovirally transduced mouse myoblast. Briefly, primary
mouse myoblasts, which already expressed LacZ from a
different retroviral construct [22] were transduced with a
bicistronic retroviral vector expressing mouse VEGF164
linked to a truncated version of mouse CD8 that acted as a
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convenient cell-surface reporter gene as previously
described [18]. Based on the VEGF secretion rates deter-
mined by ELISA, we selected 2 clones expressing specific
low and high VEGF164 doses (VLow = 61.0 ± 2.9 and
VHigh = 121.0 ± 14.6 ng/10
6 cells/day), previously shown
to induce normal and therapeutic angiogenesis, or aberrant
angioma growth, respectively [2, 3, 18]. It should be noted
that both populations, even the VLow, were previously shown
to lead to significantly higher VEGF levels in implanted
muscles than those achievable by up-regulation of the
endogenous promoter after ischemia [3]: these doses were
selected because lower levels of expression were previously
shown to be insufficient to bring therapeutic benefit [3].
After implantation, a large proportion of myoblasts dies and
up to 10 % stably engraft [27]. We therefore verified the
level of exogenous VEGF expression in vivo normalized by
the number of surviving cells at each time-point by qRT-
PCR. As expected in view of the known methylation and
partial silencing of the retroviral LTR promoter [28], we
found that VEGF expression per cell decreased in both VLow
and VHigh populations (by about 60 and 20 %, respectively)
between day 0 and day 7 after implantation in TA muscles
(data not shown).
Myoblasts transduced to express mouse CD8 but no
VEGF were used as control. Myoblast clonal populations
were implanted into the posterior auricular muscle of SCID
mice, as the ear microenvironment is thin and particularly
advantageous for visualization of the entire vascular
architecture and into the Tibialis Anterior (TA) and Gas-
trocnemius Lateralis (GC) muscles in the hind limb, as the
target of therapeutic approaches are the leg muscles.
Control myoblasts did not alter the pre-existing vasculature
at any time point and were surrounded by morphologically
normal capillaries (Fig. 1a, e), covered with pericytes
positive for nerve/glial antigen 2 (NG2) (Figs. 2a, d, 3a, d).
Four days after myoblast implantation, both clones induced
a marked enlargement of the pre-existing vessels
(Figs. 1b–c, 2b–c, 3b–c) compared with controls.
Quantification of vessel diameter distribution showed that
the degree of vascular enlargements was proportional to
VEGF dose. As shown in Fig. 1d, vessels in areas implanted
with control CD8 cells were uniformly distributed around a
median of 12.5 lm. VLow cells induced heterogeneous vas-
cular enlargements with a median of 20.4 lm and 90th per-
centile of 36.3 lm, while VHigh cells induced a significantly
greater degree of vascular enlargement, with a median of
33.5 lm and a 90th percentile of 53.9 lm (average diame-
ters: ctrl = 13.0 ± 0.4 lm, VLow = 23.5 ± 0.9 lm and
VHigh = 35.1 ± 1.0 lm; P \ 0.0001 for all the comparison).
However, by 7 days enlarged vessels remodeled differently
depending on VEGF dose, generating either normal capillary
networks (Fig. 1f, VLow), which showed well-attached NG2-
positive pericytes (Figs. 2e, 3e), or aberrant angioma-like
structures (Fig. 1g, VHigh), which lacked NG2-positive peri-
cytes and were coated instead by a thick a-SMA-positive
smooth muscle layer (Figs. 2f, 3f). At 4 days, enlarged vessels
retained NG2-positive pericytes in the presence of low VEGF
(Figs. 2b, 3b), whereas many vascular stretches were devoid
of mural cells with high VEGF (Figs. 2c, 3c). Careful analysis
of the enlarged vessel walls did not reveal any evidence of
ab-luminal sprouting, such as filopodia-bearing endothelial tip
cells, whereas intravascular protrusions were visible in all
enlarged structures at 4 days, suggestive of vascular splitting,
or intussusception (Figs. 2g–h, 3g–h). Since filopodia are not
optimally marked by CD31 expression, we also used a com-
bination of antibodies against endomucin, which homoge-
neously stains all endothelial cells, including the filopodia on
sprouting tip cells, and laminin, which labels the basal lamina
and defines the external boundary of vessels. As shown in
Supplemental Fig. 1, at 4 days the endomucin-positive cells
of enlarged vascular structures were completely contained
within the respective basal lamina and no endothelial exten-
sions could be seen protruding outside of it, thereby con-
firming the lack of signs of sprouting.
In order to verify whether VEGF diffusion and possible
gradient formation may give rise to endothelial sprouting at
a distance from the VEGF source, we specifically analyzed
vascular morphology at the borders of the myoblast
implantation areas at the 4 day time-point. However, the
angiogenic effect did not extend beyond the area of the
implanted myoblasts, exhibiting a sharp boundary within a
few microns of it, in agreement with our own previous
results with the same system [2, 29]. Such effect was
comprised of circumferential vascular enlargement and
transluminal pillar formation also on the edges of such
areas, similarly to the results described for the center of the
implantation sites (Supplemental Fig. 2).
Furthermore, we asked whether 4 days may be a too
long time-point and sprouting may be occurring earlier
after VEGF expression. However, 2 days after myoblast
implantation vessels next to the injected myoblasts did not
yet show signs of either ab-luminal sprouting or circum-
ferential enlargement (Supplemental Fig. 3), suggesting
that the enlargements that were evident by 4 days were the
first event induced by VEGF over-expression in these
conditions and also that they took place quite rapidly,
between days 2 and 4.
Vascular enlargements undergo intussusceptive
angiogenesis
Characteristic for the process of intussusception is the for-
mation of transluminal tissue pillars, which fuse progres-
sively together and split the affected vascular segment
longitudinally [11]. We addressed whether intussusception
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was occurring by the gold-standard analysis of vascular cor-
rosion casts [30]. VLow and VHigh myoblast clones and control
cells were implanted into tibialis anterior and gastrocnemius
muscles of SCID mice. Four and seven days later the entire
vasculature was cast by perfusion of polyurethane resin and
the detailed microvascular morphology was observed by
scanning electron microscopy. Control myoblasts did not
perturb the pre-existing vasculature at any time-point
(Fig. 4a–b, g–h). At 4 days, enlarged vessels induced by both
VEGF doses displayed numerous tiny holes that pierced
through the vessel casts (Fig. 4c–f), caused by the initial
formation of transluminal pillars. By 7 days, vascular casts
showed evidence of segregation of new capillary segments by
intraluminal pillar fusion in the presence of low VEGF
(Fig. 4i–j). In contrast, the aberrant bulbous angioma-like
structures induced by high VEGF no longer showed any signs
of intraluminal pillar formation (Fig. 4k–l). The occurrence
of intussusceptive angiogenesis was quantified at 4 days by
measuring the numerical density of pillars, defined as the total
number of pillars per mm2 of vascular surface area. As show
in Fig. 4m, the results confirmed the absence of intussus-
ceptive events in control tissues and showed abundant pillar
formation in both VLow and VHigh conditions
(VLow = 269.6 ± 43.5 and VHigh = 542.4 ± 138.1;
*P \
0.01 and **P \ 0.001 vs control, respectively). To determine
the morphological substrate of the holes observed in the
vascular casts, 3D reconstruction of vascular structures was
performed from serial semi-thin sections of both TA and GC
muscles. Neither vascular cast analysis nor 3D reconstruction
of semi-thin sections are capable of positively identifying
sprouting tip cells, but they are ideal to show the presence and
structure of intraluminal processes. This analysis confirmed
that the visible holes represented transluminal pillars (Fig. 5).
At 4 days, enlarged vessels displayed the presence of both
intraluminal protrusions made exclusively of endothelial cells
and mature, matrix-filled complete pillars, indicated by
arrowheads and arrows, respectively, in Fig. 5a–f. By 7 days,
fusion of adjacent pillars led to splitting into regular capillary
Fig. 1 Vascular morphology 4 and 7 days after over-expression of
different VEGF doses. Two clonal populations of transduced
myoblasts expressing either a low or a high VEGF dose (Vlow and
Vhigh, respectively), and control myoblasts expressing only CD8 (ctrl)
were injected in the posterior auricularis muscle. The angiogenic
response was analyzed in tissue whole-mounts by lectin staining
(brown) and myoblast engraftment was tracked by X-Gal staining
(blue–green). a–c Vascular morphology 4 days after cell
implantation. Arrowheads indicate the diameters of markedly
enlarged vessels at the sites of VEGF over-expression. d The
distribution of vessel diameters was quantified in areas implanted
with each cell population. e–g By 7 days, control myoblasts did not
alter the pre-existing vasculature, whereas enlarged vessels remodeled
into morphologically normal capillaries (arrows, VLow) or aberrant
angioma-like structures (stars, VHigh). n = 6 ears per group, per time-
point; size bars = 50 lm. (Color figure online)
128 Angiogenesis (2013) 16:123–136
123
segments with low VEGF (Fig. 5g–i), whereas aberrant
structures induced by high VEGF displayed only rare fully
mature pillars separating large vascular lacunae (Fig. 5j–l).
Vascular enlargement is associated with endothelial
proliferation and increased blood flow
Vascular enlargement can be due either to expansion of the
number of endothelial cells through proliferation or to
extension of their surface by thinning and spreading of indi-
vidual cells, which has been described to occur in the first
Fig. 2 Mural cell coverage and endothelial morphology during vascu-
lar remodeling in ear muscle. Control cells, VLow and VHigh myoblast
clones were implanted in the posterior auricularis muscle and the
induced angiogenesis was analyzed 4 and 7 days later. Whole-mount
immunostaining of blood vessels was performed with antibodies against
CD31 (endothelial cells, red), NG2 (pericytes, green), a-SMA (smooth
muscle cells, cyan) and with DAPI (nuclei, blue). a–c By 4 days, VEGF
caused vascular enlargements (arrowheads) which were associated with
normal NG2? pericytes (VLow) or were mainly devoid of mural cell
(VHigh), depending on VEGF dose. d–f By 7 days, vascular enlarge-
ments remodeled in networks of morphologically normal and mature
capillaries, as shown by the NG2? pericyte coverage (arrows, VLow) or
into aberrant angioma-like structures, which lacked pericytes and were
covered with a thick smooth muscle coat (arrows, VHigh). White
asterisks mark the implanted myoblasts. g–h At 4 days enlarged vessels
(outlined by dashed lines) showed no evidence of sprout formation and
were pierced by numerous trans-luminal holes at both VEGF doses
(white dots). n = 2 ears per group, per time-point; size bars = 30 lm.
(Color figure online)
Fig. 3 Mural cell coverage and endothelial morphology during
vascular remodeling in limb muscles. Vessels induced by implanta-
tion of VLow and VHigh myoblast clones were immunostained with
antibodies against CD31 (endothelial cells, red), NG2 (pericytes,
green), a-SMA (smooth muscle cells, cyan) and with DAPI (nuclei,
blue) in cryosections of implanted TA and GC muscles. a–c By
4 days, VEGF caused vascular enlargements (arrowheads) which
were associated with normal NG2? pericytes (VLow) or were mainly
devoid of mural cell (VHigh), depending on VEGF dose. d–f By
7 days, these vascular enlargements remodeled in networks of mature
capillaries, as shown by the NG2? pericyte coverage (arrows, VLow)
or into aberrant dilated angioma-like structures, which lacked
pericytes and were covered with a thick smooth muscle coat (star,
VHigh). g–h At 4 days enlarged vessels (outlined by dashed lines)
showed no evidence of sprout formation and were pierced by
numerous trans-luminal holes at both VEGF doses (white dots). n = 3
muscles per group, per time-point; size bars = 20 lm. (Color figure
online)
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Fig. 4 Scanning electron microscopy analysis of vascular casts.
Control cells, VLow and VHigh myoblast clones were implanted in TA
and GC muscles of SCID mice and vascular corrosion casts of the entire
legs were performed 4 and 7 days post-implantation. a–f At 4 days,
enlarged vessels displayed signs of transluminal pillar formation,
represented by the numerous small indentations and holes indicated by
the black arrows. g–l At 7 days, low VEGF formed normal capillary
networks by intussusceptive splitting (VLow), whereas angioma-like
structures caused by high VEGF (star, VHigh) did not show any further
signs of pillar formation. n = 3–4 muscles per group, per time-point.
m Quantification of the numerical pillar density (number of pillars per
mm2 of vessel surface area) in vascular casts 4 days after myoblast
implantation. *P \ 0.01 and **P \ 0.001; n = 2 muscles per group.
Panels b, d, f, h, j and l (size bars = 10 lm) show higher magnification
views of the areas indicated by the black squares in panels a, c, e, g, i
and k, respectively (size bars = 25 lm)
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24 h after delivery of a VEGF-expressing adenovirus [31].
Ki67 staining on frozen sections of TA and GC muscles
showed that the initial vascular enlargement at 4 days was
associated with active endothelial proliferation (Fig. 6a–b).
Quantification of the amount of proliferating endothelial
nuclei showed no differences between VEGF doses (Fig. 6e,
VLow = 81.8 ± 0.7 % and VHigh = 84.8 ± 1.3 %). By
7 days, the endothelium of normal capillary networks was
almost completely quiescent, whereas that of angioma-like
structures continued proliferating (Fig. 6c–e; VLow = 7.1 ±
1.3 % and VHigh = 50.1 ± 2.3 %,
***P \ 0.0001). Further-
more, Ki67 staining did not reveal any endothelial prolifer-
ation 2 days after implantation of either VLow or VHigh
myoblasts (data not shown).
Quantitative gene expression analysis by qRT-PCR
(Fig. 7) showed that the initial vascular enlargement by
both VEGF doses was associated with a markedly
increased expression of the flow-dependent genes Kru¨ppel-
like factor-2 (KLF2) and endothelial nitric oxide synthase
(eNOS) at 4 days, suggesting that the endothelium of these
structures was exposed to increased flow and shear stress.
Consistently with the observed vascular morphology, by
7 days expression of both markers remained elevated with
high VEGF, but returned to control levels in the presence
of low VEGF and normal capillary remodeling.
VEGF over-expression causes intussusceptive
angiogenesis also after adenoviral delivery
Lastly, we sought to determine whether VEGF over-
expression by an unrelated and clinically relevant gene
delivery system would also induce angiogenesis in skeletal
Fig. 5 3D reconstructions from serial semi-thin sections. Four and
seven days after injection of VLow and VHigh clones, hundreds of
serial semi-thin sections were obtained from TA and GC muscles and
the corresponding 3D stacks were generated from the individual
images. a–f At 4 days, reconstructed lumen borders (red) of enlarged
vessels display both mature trans-luminal pillars (arrows) and
emerging intraluminal protrusions (arrowheads) built exclusively by
endothelial cells. g–l At 7 days, trans-luminal mature pillars (arrows)
segregate new normal capillary segments with low VEGF (VLow) and
separate large aberrant vascular lacunae with high VEGF (VHigh). The
panels in the left column display overviews of the areas of effect, the
panels in the middle column display reconstructed surfaces at a higher
magnification from a different perspective, and panels in the right
column display a virtual section through the obtained 3D stacks.
n = 3 muscles per group, per time-point; size bars = 10 lm. (Color
figure online)
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muscle by intussusception rather than sprouting. To test
this hypothesis, adenoviral vectors, expressing VEGF164 or
just a truncated CD8 molecule as control (Ad-VEGF and
Ad-CD8) [32], were implanted in TA muscles. Immuno-
staining of frozen tissue sections and confocal microscopy
showed that, while Ad-CD8 did not affect the pre-existing
vasculature (Fig. 8a–b), by 4 days Ad-VEGF caused seg-
mental enlargements in existing vessels, without signs of
sprouting, but with evidence of trans-luminal pillar for-
mation (Fig. 8c). Enlarged vessels subsequently remodeled
into angioma-like structures covered by a thick a-SMA-
positive smooth muscle coat (Fig. 8d), similarly to the
effects of high-dose VEGF expression by transduced
myoblasts. Ki67 staining confirmed that also in this case
[70 % of endothelial cells in the initial vascular enlarge-
ments at 4 days were actively proliferating (Fig. 8e–f,
AdVEGF = 71.7 ± 3.4 %).
Discussion
By using a highly controlled cell-based gene delivery plat-
form, we could study how angiogenesis is induced by over-
expression of specific VEGF doses: one that we have pre-
viously shown to be therapeutic and safe in a model of
hindlimb ischemia, and one that instead caused angioma
growth [3]. Our data from 3 independent and complementary
methods (confocal microscopy, vascular casting and 3D
reconstruction of serial semi-thin sections) show that in both
cases new vascular growth took place essentially without
sprouting, but rather by an initial circumferential enlarge-
ment of pre-existing vessels and VEGF-induced endothelial
proliferation. This in turn was associated with increased flow
and shear stress, as evidenced by the up-regulation of the
Fig. 6 Vascular enlargement is associated with endothelial prolifer-
ation. a–d Immunostaining with antibodies against CD31 (endothelial
cells, green), Ki67 (proliferating cells, red) and with DAPI (nuclei,
blue) was performed on cryosections of TA and GC muscles 4 and
7 days after myoblast implantation. Vessels are outlined by dashed
lines, arrowheads point to proliferating nuclei of endothelial cells and
asterisks indicate the lumens of large aberrant angioma-like struc-
tures. e The percentage of proliferating endothelial cells was
quantified in areas of effect, ***P \ 0.0001; n = 3 muscles per
group, per time-point; size bars = 20 lm. (Color figure online)
Fig. 7 Vascular enlargement causes increased flow. Total RNA was
extracted from TA and GC muscles harvested 4 and 7 days after
implantation with control cells (Ctrl), VLow and VHigh myoblast
clones. Expression of the flow-dependent genes Klf2 and eNOS was
quantified in triplicate by qRT-PCR and normalized to that of the
housekeeping gene GAPDH. *P \ 0.05 versus control; n = 4 mus-
cles per group, per time-point
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transcription factor Klf2, that mediates endothelial responses
to shear stress [33, 34]. These hemodynamic stimuli are
potent triggers for intussusception [16]. In fact, acute
increases in flow and shear stress in microvascular networks
have been found to rapidly initiate pillar formation and
capillary splitting even without endothelial proliferation or
growth factor delivery [12, 35]. We have previously shown
that clamping of arterial side-branches in fully mature
16-day-old chicken chorioallantoic membranes led to a
greater than 50 % increase in the downstream flow rate and
the appearance of transluminal pillars in capillaries as early
as 40 min later [35]. The immediacy of the response indi-
cates that the hemodynamic trigger is sufficient and does not
require changes in gene expression to initiate the intussus-
ceptive process. Hudlicka and coworkers further demon-
strated that treatment with the a1-adrenergic receptor blocker
prazosin, which increases blood flow and shear stress in the
downstream microvascular networks purely through arterial
vasodilation, induced vascular growth in skeletal muscle by
capillary splitting without any proliferation of endothelial
cells [12].
Interestingly, our data also suggest that pericytes are not
necessary to initiate intussusception. In fact, 4 days after
high VEGF expression enlarged vessels were mostly
devoid of pericytes, in agreement with the recently
described negative regulation of pericytes by VEGF [36],
yet pillar formation took place unimpeded and no NG2?
cell could be found in association with the initiating
endothelial invaginations (Figs. 2h, 3h).
Since different muscles have different vessel densities
depending on whether they are composed prevalently of
anaerobic fast-twitch or glycolytic slow-twitch fibers [37],
it would be interesting to understand whether VEGF over-
expression may have different outcomes depending on the
muscle metabolic type. Unfortunately, both the TA and the
GC muscles, which we injected, belong to the fast type,
although the GC contains a small (3 %) proportion of type
1 slow-twitch fibers in the internal part [37], and therefore
our results do not allow an answer to this question, which
should be addressed by ad hoc systematic experiments.
During sprouting, specialized endothelial tip cells are
formed that sense a VEGF gradient through filopodia
extensions and migrate towards it, while stalk cells prolif-
erate behind to form the new vessel lumen [7]. If a VEGF
gradient is lacking, e.g. when the non-matrix-binding iso-
form VEGF121 is expressed, endothelial cells proliferate
without migrating and lead to vessel enlargement instead
[38]. Our data indicate that over-expression of the matrix-
binding VEGF164 at two different supra-physiologic doses
induced vascular enlargement with robust endothelial pro-
liferation in the absence of migrating tip cells, followed by
transluminal pillar formation and intussusceptive remodel-
ing. Indeed, vascular enlargement per se can induce
Fig. 8 VEGF adenoviral delivery causes endothelial proliferation and
vascular enlargements that remodel by intussusception. a–d Vascular
morphology was analyzed 4 and 7 days after injection in TA muscles of
adenoviruses expressing VEGF (Ad-VEGF) or only CD8 as control (Ad-
CD8) by immuno-fluorescent staining for CD31 (endothelial cells, red),
NG2 (pericytes, green), a-SMA (smooth muscle cells, cyan) and DAPI
(nuclei, blue) on cryosections. Control Ad-CD8 did not affect normal
capillaries lining muscle fibers at either time-point (a, b). Ad-VEGF
caused vascular enlargement (arrows in c), with no signs of extraluminal
sprouts and showing evidence of trans-luminal pillar formation, both
incipient (white dots in c) and more mature, with the presence of a
pericyte (arrowhead in c). These enlargements remodeled into angioma-
like structures by 7 days (asterisks in d). n = 3 muscles per group, per
time-point; size bars = 20 lm. e Immunofluorescence staining with
antibodies against CD31 (endothelial cells, green), Ki67 (proliferating
cells, red) and DAPI (nuclei, blue) on cryosections of TA muscles 4 days
after Ad-VEGF injection. A vascular enlargement is outlined by dashed
lines, while arrowheads point to the nuclei of proliferating endothelial
cells. f The percentage of proliferating endothelial cells was quantified in
areas of effect. n = 2 muscles; size bars = 20 lm. (Color figure online)
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endothelial proliferation [39], but we also have previously
found that, in this system, initial vascular enlargement
depends on VEGF signaling and regresses completely after
treatment with a VEGF-Trap [2]. On the other hand,
sprouting has been reported to take place during spontaneous
angiogenesis after skeletal muscle ischemia, although an
attempt to stimulate this process by systemic inhibition of
Dll4/Notch1 signaling did not result in ischemia improve-
ment, but actually led to an increase in dysfunctional angi-
ogenesis [10]. The absence of any sprouting we found is
likely due to differences in the VEGF dose achieved in tissue.
In fact, as VEGF accumulates in the limited amount of
extracellular matrix between muscle fibers, it can saturate the
microenvironment and abolish the formation of a gradient
capable of inducing tip cell migration. Indeed, we previously
found that 3 days after induction of hind-limb ischemia the
levels of endogenous VEGF moderately increased about
3-fold, whereas treatment with the low VEGF-expressing
myoblast clone used here, that was both therapeutic and safe
in the same experiments, led to an 18-fold increase in muscle
VEGF concentration [3]. Taken together, these results sug-
gest that VEGF doses higher than the maximal up-regulation
achieved by the endogenous response are necessary for
therapeutic benefit, but induce angiogenesis by a different
mechanism. In agreement with our findings, a recent dose-
escalation study of adenoviral VEGF delivery to rabbit
skeletal muscle showed that sprouting occurred with low
VEGF and capillary enlargement with higher doses, but
functional benefits were seen only with enlarged vessels [40].
In that study, the mechanisms of new vessel formation after
initial enlargement could not be investigated due to the short-
term duration of adenoviral expression in immunocompetent
animals, but the complete switch from sprouting to vessel
enlargement, as well as the maximal perfusion improvement,
occurred with adenoviral titers from 1010 particles/ml, cor-
responding to about 5 9 108 infectious units/ml, and higher
[40]. This is in good agreement with our results reported here
that show absence of sprouting with an adenoviral titer of
5 9 109 infectious units/ml.
On the basis of our results, it is possible to speculate on
how the same process of intussusception may result in
either normal or aberrant angiogenesis depending on the
VEGF dose. In fact, the density of pillars that form per unit
of vascular surface area at 4 days is not statistically dif-
ferent between low and high VEGF doses (Fig. 4m).
However, the high VEGF dose caused vessels to enlarge
significantly more at this stage than the low VEGF dose,
with more than 50 % of the structures having a diameter
[30 lm (Fig. 1d). It is therefore plausible that, while pillar
formation is initiated in both cases by the increased shear
stress that follows enlargement, mature pillars may fail to
complete in the presence of an excessive diameter to
bridge, causing the affected vascular segments to continue
growing into angioma-like structures. On the other hand,
the successful completion of intussusceptive remodeling in
smaller-caliber vascular enlargements would generate the
normal capillary networks observed with low VEGF. High-
resolution time-lapse in vivo imaging experiments will be
required to validate this hypothesis.
From a functional point of view, simulations with a
computational model have shown that vascular networks
induced by intussusception and by sprouting are similarly
effective under steady-state conditions of moderate oxygen
consumption [41]. However, the same computational model
also found that intussusceptive networks become more
effective in oxygen delivery under conditions of high meta-
bolic demand. Furthermore, intussusception has the potential
to provide more rapid functional relief in conditions of
ischemia. In fact, the very initial stage of intussusception, i.e.
vascular enlargement, ensures an immediate increase in flow
in the affected region, whereas sprouts are not functional
until fusion with another sprout allows effective flow to start
in the new vessel [16]. The greater functional efficacy of
vascular enlargement compared to sprouting was also shown
by the dose-escalation study of adenoviral VEGF delivery to
rabbit skeletal muscle described above [40]. The rapid
increase in flow and shear stress caused by initial vascular
enlargement also triggers intussusceptive remodeling [16],
thereby limiting flow in each of the resulting normal-size
microvessels to physiological levels and returning the system
to the steady-state.
In conclusion, our results show that VEGF over-
expression in skeletal muscle, at the doses required to
induce functional benefit, induces vascular growth preva-
lently by intussusception rather than sprouting. Therefore,
for the rational design of novel therapeutic angiogenesis
approaches, it will be key to elucidate the molecular
mechanisms controlling intussusception, which are still
poorly understood compared to sprouting due to a paucity
of appropriate models. The cell-based platform used in this
work for controlled expression of specific VEGF doses in
skeletal muscle, based on monoclonal populations of
transduced myoblasts, may represent a useful such model
to study the mechanisms of intussusceptive angiogenesis in
a clinically relevant tissue.
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